Physician profile
Bryan Franklin Curtin
NPI 1437425873
$81,960.37
in general payments reported to CMS, 2019-2025
35 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.53 · 2021: $783 · 2022: $1,098 · 2023: $1,688 · 2024: $22K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $11K · Food and Beverage: $6,398 · Travel and Lodging: $2,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,525.56 |
| Consulting Fee | $11,250.00 |
| Food and Beverage | $6,397.77 |
| Travel and Lodging | $2,828.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $57,414.68 | 2022-2025 | Ibsrela |
| Abbvie INC. | $20,273.81 | 2021-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,130.32 | 2021-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $477.01 | 2021-2025 | Sucraid, Sucraid |
| Vibrant Gastro, INC. | $392.88 | 2023-2024 | Vibrant Starter Kit |
| Medtronic, INC. | $313.20 | 2021-2024 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $285.61 | 2020-2024 | Gattex, Eohilia |
| Enterra Medical, INC. | $205.01 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $177.42 | 2022-2024 | Terlivaz |
| Aimmune Therapeutics, INC. | $132.18 | 2023-2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $122.15 | 2021-2024 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $112.69 | 2022-2025 | Givlaari |
| Ironwood Pharmaceuticals, INC | $105.73 | 2022-2023 | Linzess |
| Exelixis INC. | $86.22 | 2022-2023 | Cabometyx |
| Phathom Pharmaceuticals, INC. | $67.45 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $67.28 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $62.19 | 2021-2023 | |
| Cumberland Pharmaceuticals, INC. | $60.36 | 2021-2024 | Caldolor, Sancuso |
| Eisai INC. | $46.38 | 2023 | |
| Daiichi Sankyo INC. | $45.23 | 2021-2022 | |
| Teleflex LLC | $42.73 | 2024 | Solesta |
| Celgene Corporation | $41.07 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $36.28 | 2021-2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $35.51 | 2022-2023 | Rebyota |
| Madrigal Pharmaceuticals | $27.38 | 2025 | Rezdiffra |
| Lilly USA, LLC | $26.87 | 2024 | Omvoh |
| Evoke Pharma, INC. | $26.07 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $25.62 | 2024 | Bylvay |
| Redhill Biopharma INC. | $20.37 | 2021 | |
| Gilead Sciences, INC. | $19.08 | 2022 | |
| Laborie Medical Technologies Corp. | $18.92 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $17.71 | 2023 | |
| Amgen INC. | $16.96 | 2020 | |
| Janssen Biotech, INC. | $15.52 | 2024 | Stelara, Simponi, Tremfya |
| Digestive Care, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Curtin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.